JP2006517232A - Adhdの処置のためのエナンチオマーアンフェタミン組成物 - Google Patents

Adhdの処置のためのエナンチオマーアンフェタミン組成物 Download PDF

Info

Publication number
JP2006517232A
JP2006517232A JP2006503445A JP2006503445A JP2006517232A JP 2006517232 A JP2006517232 A JP 2006517232A JP 2006503445 A JP2006503445 A JP 2006503445A JP 2006503445 A JP2006503445 A JP 2006503445A JP 2006517232 A JP2006517232 A JP 2006517232A
Authority
JP
Japan
Prior art keywords
amphetamine
isomer
pharmaceutical combination
release
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006503445A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006517232A5 (cg-RX-API-DMAC7.html
Inventor
リチャード・エイ・カウチ
アレックス・マイケルズ
ポール・ホジキンス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shire Canada Inc
Original Assignee
Shire Canada Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shire Canada Inc filed Critical Shire Canada Inc
Publication of JP2006517232A publication Critical patent/JP2006517232A/ja
Publication of JP2006517232A5 publication Critical patent/JP2006517232A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2006503445A 2003-02-10 2004-02-10 Adhdの処置のためのエナンチオマーアンフェタミン組成物 Pending JP2006517232A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US44579303P 2003-02-10 2003-02-10
US47392503P 2003-05-29 2003-05-29
PCT/US2004/003821 WO2004071501A1 (en) 2003-02-10 2004-02-10 Enantiomeric amphetamine compositions for the treatment of adhd

Publications (2)

Publication Number Publication Date
JP2006517232A true JP2006517232A (ja) 2006-07-20
JP2006517232A5 JP2006517232A5 (cg-RX-API-DMAC7.html) 2007-04-12

Family

ID=32871959

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006503445A Pending JP2006517232A (ja) 2003-02-10 2004-02-10 Adhdの処置のためのエナンチオマーアンフェタミン組成物

Country Status (10)

Country Link
US (1) US20040220277A1 (cg-RX-API-DMAC7.html)
EP (1) EP1626709B1 (cg-RX-API-DMAC7.html)
JP (1) JP2006517232A (cg-RX-API-DMAC7.html)
KR (1) KR20050119106A (cg-RX-API-DMAC7.html)
AT (1) ATE372112T1 (cg-RX-API-DMAC7.html)
AU (1) AU2004210671A1 (cg-RX-API-DMAC7.html)
CA (1) CA2515394A1 (cg-RX-API-DMAC7.html)
DE (1) DE602004008771T2 (cg-RX-API-DMAC7.html)
ES (1) ES2293223T3 (cg-RX-API-DMAC7.html)
WO (1) WO2004071501A1 (cg-RX-API-DMAC7.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6913768B2 (en) * 2002-09-24 2005-07-05 Shire Laboratories, Inc. Sustained release delivery of amphetamine salts
EP1874274A2 (en) * 2005-04-06 2008-01-09 Mallinckrodt Inc. Matrix-based pulse release pharmaceutical formulation
WO2007041571A1 (en) * 2005-10-03 2007-04-12 Cambrex Charles City, Inc. Improved method of making amphetamine free base
ATE536867T1 (de) 2006-03-16 2011-12-15 Tris Pharma Inc Modifizierte freisetzungsformulierungen mit arznei-ion-austausch-harzkomplexen
GB201002612D0 (en) * 2010-02-16 2010-03-31 Jagotec Ag Improvements in or relating to organic compounds
US10463633B2 (en) * 2010-04-23 2019-11-05 Kempharm, Inc. Therapeutic formulation for reduced drug side effects
US8287903B2 (en) 2011-02-15 2012-10-16 Tris Pharma Inc Orally effective methylphenidate extended release powder and aqueous suspension product
US9603809B2 (en) 2011-03-23 2017-03-28 Ironshore Pharmaceuticals & Development, Inc. Methods of treatment of attention deficit hyperactivity disorder
US11241391B2 (en) 2011-03-23 2022-02-08 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9498447B2 (en) 2011-03-23 2016-11-22 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9283214B2 (en) 2011-03-23 2016-03-15 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US10292937B2 (en) 2011-03-23 2019-05-21 Ironshore Pharmaceuticals & Development, Inc. Methods of treatment of attention deficit hyperactivity disorder
US9119809B2 (en) 2011-03-23 2015-09-01 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US10905652B2 (en) 2011-03-23 2021-02-02 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
WO2013059676A1 (en) * 2011-10-21 2013-04-25 Subhash Desai Compositions for reduction of side effects
US11590228B1 (en) 2015-09-08 2023-02-28 Tris Pharma, Inc Extended release amphetamine compositions
IL288554B2 (en) * 2016-02-24 2024-02-01 Chemapotheca LLC Controlled release of amphetamine, drug meters and dosage forms with abuse deterrence
US11590081B1 (en) 2017-09-24 2023-02-28 Tris Pharma, Inc Extended release amphetamine tablets
US12458592B1 (en) 2017-09-24 2025-11-04 Tris Pharma, Inc. Extended release amphetamine tablets
CA3221280A1 (en) 2021-06-03 2022-12-08 Arcadia Medicine, Inc. Enantiomeric entactogen compositions and methods of their use
CA3239514A1 (en) * 2021-12-09 2023-06-15 Matthew J. Baggott Specialized combinations for mental disorders or mental enhancement

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6322819B1 (en) * 1998-10-21 2001-11-27 Shire Laboratories, Inc. Oral pulsed dose drug delivery system
JP2006503071A (ja) * 2002-09-24 2006-01-26 シャイア ラボラトリーズ,インコーポレイテッド アンフェタミン塩の持続放出型送達

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6056968A (en) * 1997-03-11 2000-05-02 Darwin Discovery Limited Pharmaceutical drug dosage forms providing different release rates
WO2000059481A1 (en) * 1999-04-06 2000-10-12 Pharmaquest Ltd. PHARMACEUTICAL DOSAGE FORM FOR PULSATILE DELIVERY OF d-threo-METHYLPHENIDATE AND A SECOND CNS STIMULANT
TWI291871B (en) * 2000-11-01 2008-01-01 Cognition Pharmaceuticals Llc Pharmaceutical compositions and use of amphetamine compounds for improving memory and learning
AU2003208170B2 (en) * 2002-02-28 2006-11-23 Birseck Pty Ltd Treatment of effect of chemicals with their ultradilute stereoisomers
AU2003231156A1 (en) * 2002-04-30 2003-11-17 Npd Llc Multi-phasic delivery via transmucosal absorption of appetite suppressants and craving reduction medicaments

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6322819B1 (en) * 1998-10-21 2001-11-27 Shire Laboratories, Inc. Oral pulsed dose drug delivery system
JP2002527468A (ja) * 1998-10-21 2002-08-27 シャイア ラボラトリーズ,インコーポレイテッド 脈動用量薬剤経口送達システム
JP2006503071A (ja) * 2002-09-24 2006-01-26 シャイア ラボラトリーズ,インコーポレイテッド アンフェタミン塩の持続放出型送達

Also Published As

Publication number Publication date
ES2293223T3 (es) 2008-03-16
KR20050119106A (ko) 2005-12-20
WO2004071501A1 (en) 2004-08-26
DE602004008771D1 (de) 2007-10-18
CA2515394A1 (en) 2004-08-26
HK1091117A1 (en) 2007-01-12
EP1626709B1 (en) 2007-09-05
DE602004008771T2 (de) 2008-06-12
ATE372112T1 (de) 2007-09-15
EP1626709A1 (en) 2006-02-22
US20040220277A1 (en) 2004-11-04
AU2004210671A1 (en) 2004-08-26

Similar Documents

Publication Publication Date Title
EP1626709B1 (en) Enantiomeric amphetamine compositions for the treatment of adhd
CA2499546C (en) Sustained released delivery of amphetamine salts
US9173857B2 (en) Controlled dose drug delivery system
MX2013010920A (es) Metodos y composiciones para el tratamiento de transtorno por deficit de atencion.
JP7504488B2 (ja) マジンドールのir/sr多層錠剤及び該錠剤の注意欠陥/多動性障害(adhd)の治療のための使用
US20250228802A1 (en) Extended release midodrine hydrochloride compositions and methods of use
ES2529455T3 (es) Sistema de administración de fármacos por dosis controladas
US20180015080A1 (en) Compositions and methods for treatment in parkinson's disease patients
CZ298851B6 (cs) Tableta pro rízené podávání úcinných látek
JP2006517232A5 (cg-RX-API-DMAC7.html)
US20220241222A1 (en) Atomoxetine hydrochloride extended release compositions and methods of use
HK1091117B (en) Enantiomeric amphetamine compositions for the treatment of adhd
MXPA05008448A (en) Enantiomeric amphetamine compositions for the treatment of adhd
KR20240006643A (ko) 삼봉 정밀-시한 펄스형 방출 정제
US20160008335A1 (en) Pharmaceutical compositions of donepezil having specific in vitro dissolution profile or pharmacokinetics parameters
HK40002539A (en) A mazindol ir/sr multilayer tablet and its use for the treatment of attention deficit/hyperactivity disorder (adhd)
HK1127471A (en) Methods of treating central nervous system disorders with a low dose combination of escitalopram and bupropion

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070202

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070202

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070214

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100713

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20101207